Baird Medical Investment Holdings Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $22.5M | $37.0M | $31.5M | $35.1M |
| Cost of Revenue | $3.7M | $4.4M | $4.2M | $7.1M |
| Gross Profit | $18.9M | $32.7M | $27.2M | $28.0M |
| Gross Margin | 83.8% | 88.2% | 86.6% | 79.9% |
| Operating Expenses | ||||
| Research & Development | $20.1M | $6.2M | $4.3M | $3.9M |
| SG&A Expense | $14.1M | $7.1M | $8.5M | $7.0M |
| Operating Income | $-25.6M | $15.3M | $11.9M | $13.6M |
| Operating Margin | -113.7% | 41.4% | 37.7% | 38.8% |
| Interest Expense | $354.3K | $388.6K | $227.9K | $243.8K |
| Pretax Income | $-26.4M | $14.1M | $12.4M | $14.5M |
| Income Tax Expense | $1.2M | $1.5M | $1.7M | $1.7M |
| Net Income | $-27.3M | $12.5M | $10.5M | $12.8M |
| Net Margin | -121.0% | 33.6% | 33.5% | 36.4% |
| EPS (Basic) | $-0.98 | $0.57 | $0.51 | $0.49 |
| EPS (Diluted) | $-0.98 | $0.57 | $0.51 | $0.49 |
| Shares Outstanding (Basic) | 27.8M | 21.8M | 20.6M | 25.6M |
| Shares Outstanding (Diluted) | 27.8M | 21.8M | 20.6M | 25.6M |
| Dividends Per Share | — | — | — | — |